Cizzle Bio Submits NIH Grant Proposal with Top-Tier Research Institutions to Advance Early Detection of Lung Cancer
Cizzle Bio, Inc. has submitted a grant application to the National Institutes of Health (NIH), in partnership with two leading research institutions, to further validate the CIZ1B biomarker blood test—an innovative tool for the early detection of lung cancer. Lung cancer is the leading cause of cancer-related deaths in the U.S. and globally, primarily because it is often diagnosed at advanced stages. Cizzle Bio’s CIZ1B blood test, an ELISA-based assay, has shown high sensitivity and specificity in earlier studies of Stage 1 lung cancer.
This proposal for a two-year study, submitted in collaboration with premier research institutions—the Florida Institute for Human and Machine Cognition (IHMC) and the Southwest Research Institute (SwRI)—aims to further validate the test’s effectiveness in identifying lung cancer in patients before symptoms appear. IHMC will apply deep learning models and leverage the University of Florida’s HiPerGator supercomputer to uncover predictive patterns in CIZ1B expression. SwRI will lead biomarker assay validation and provide analytical expertise.
Study Design and Scientific Innovation
If awarded, the NIH-funded study will:
Analyze a large cohort of 1,730 lung cancer cases from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a landmark biorepository managed by the National Cancer Institute (NCI).
Assess biomarker accuracy across demographics (age, gender, ethnicity, smoking history)
Identify early biological signals that precede clinical diagnosis
Evaluate biomarker performance across different lung cancer subtypes
Read the Full Press Release
To learn more about the study, research partners, and the potential for this innovative research to advance early detection of lung cancer, read the full press release on PR Newswire:
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions
